In addition, nilotinib treatment (150 mg and/or 300 mg, p.o., for 26 weeks) significantly reduces Aβ burden, α-synuclein oligomers and phospho-tau-181 in the CSF in AD patients [12, 14]. Here, MAPT is linked to Alzheimer disease.